Health Condition 1: K769- Liver disease, unspecified
Conditions
Interventions
Intervention1: ROTEM Group: In ROTEM group if CT EXTEM 80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM 35 and MCF FIBTEM 8 CRYO or Fibrinogen concentrate, if MCF EXTEM35 and MCF FIBTEM 8 Pl
a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm
and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°
Duration: Till the bleeding episodes stops
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Cirrhosis of any etiology 2. Age between 18 and 80 years; 3. Presenting with nonvariceal upper GI bleeding (diagnosed after doing upper GI endoscopy, which showed ongoing 4. bleed form a nonvariceal source); and 5. Significant coagulopathy assessed by CCTs (INR > 1.8 and/or PLTs
Exclusion criteria
Exclusion criteria: 1. Variceal bleed 2. Post Variceal ligation ulcer bleed 3. Previous or current thrombotic events defined as any documented blood clot in a venous or arterial vessel; 4. Anti-PLT or anticoagulant therapy at the time of enrollment or that had been discontinued less than 7 days before evaluation for the study; 5. Pregnancy 6. Significant cardiopulmonary diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative volume of FFP transfused at Day 5.Timepoint: Day 5. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative volume of Cryoprecipitate, Platelet and Trenaxemic acid Transfusion related reactions Timepoint: Week 6;Duration of intensive care unit (ICU) and hospital stay; and Survival at 6 weeks Timepoint: Week 6 | — |
Countries
India
Contacts
Public ContactDr Manoj Kumar Sharma
Institute of Liver and Biliary Sciences
Outcome results
None listed